Scarica l'app Stockscreener
10.19
0.78%
-0.08
Precedente Chiudi:
$10.27
Aprire:
$10.42
Volume 24 ore:
253.58K
Relative Volume:
0.56
Capitalizzazione di mercato:
$430.01M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-2.7766
EPS:
-3.67
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
+2.62%
1M Prestazione:
-4.23%
6M Prestazione:
-35.47%
1 anno Prestazione:
-31.01%
Intervallo 1D:
$10.00
$10.46
Intervallo di 1 settimana:
$10.00
$10.96
Portata 52W:
$9.78
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Nome
Urogen Pharma Ltd
Settore
Industria
Telefono
972 9 770 7601
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Confronta URGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
10.19 | 430.01M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Guggenheim | Buy |
| 2023-02-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-27 | Iniziato | Berenberg | Buy |
| 2020-04-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-13 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | National Securities | Neutral |
| 2019-05-30 | Iniziato | JP Morgan | Neutral |
| 2019-05-29 | Iniziato | Goldman | Neutral |
| 2019-01-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-04-04 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-11-15 | Reiterato | Oppenheimer | Outperform |
| 2017-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mostra tutto
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Bladder Cancer Clinical and Non-Clinical Studies, Key - openPR
Barclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Barclays PLC - MarketBeat
UroGen Pharma Reveals Promising Developments in Latest 8-K Filing - Defense World
UroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at D. Boral Capital - MarketBeat
UroGen's UGN-102 shows high response in bladder cancer study By Investing.com - Investing.com South Africa
ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 - BioSpace
UroGen's UGN-102 shows high response in bladder cancer study - Investing.com
UroGen's Bladder Cancer Drug Shows 82% Response Rate in Phase 3 Trial, Aims for FDA First - StockTitan
Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67% - Simply Wall St
UroGen Pharma Highlights RTGel® Platform and Growth Plans - TipRanks
Jane Street Group LLC Sells 8,198 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
How To Trade (URGN) - Stock Traders Daily
Geode Capital Management LLC Purchases 34,248 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Has $759,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Barclays PLC Boosts Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - Yahoo Finance
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Consensus Target Price from Brokerages - MarketBeat
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by State Street Corp - Defense World
Fmr LLC Buys 19,670 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
URGN stock touches 52-week low at $10.6 amid market challenges - Investing.com Canada
URGN stock touches 52-week low at $10.6 amid market challenges By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Grows Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Charles Schwab Investment Management Inc. Increases Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Analysts Set UroGen Pharma Ltd. (NASDAQ:URGN) PT at $43.70 - MarketBeat
UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital - MarketBeat
Point72 Asset Management L.P. Cuts Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
(URGN) Investment Report - Stock Traders Daily
UroGen Pharma Grants 112,800 RSUs to Expand Commercial Team for Jelmyto Rollout - StockTitan
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Urogen Pharma Ltd. Announces Long-Term Follow-Up Study to the Olympus Trial Presented At SUO 2024 - Marketscreener.com
UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire
URGN (UroGen Pharma) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com
UroGen Pharma Ltd. (NASDAQ:URGN) Holdings Raised by RTW Investments LP - MarketBeat
Parkman Healthcare Partners LLC Has $4.41 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade - Yahoo Finance
UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - BioSpace
UroGen Pharma Unveils Key Clinical Data for Cancer Treatment Pipeline at SUO 2024 - StockTitan
URGN (UroGen Pharma) Shares Outstanding (EOP) : 42.19 Mil (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) 3-Year Revenue Growth Rate : 74.30% (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) Shares Outstanding (EOP) : 36.13 Mil (As of Sep. 2024) - GuruFocus.com
UroGen Pharma (FRA:UR8) PE Ratio without NRI : At Loss (As of Dec. 01, 2024) - GuruFocus.com
Vestal Point Capital LP Makes New Investment in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment - Clinical Trials Arena
Financial Review: UroGen Pharma (NASDAQ:URGN) and Amphastar Pharmaceuticals (NASDAQ:AMPH) - Defense World
Great Point Partners LLC Has $9.64 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
JELMYTO shows long-term efficacy in UTUC study - Investing.com India
New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO - Business Wire
URGN (UroGen Pharma) GF Value Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
Urogen Pharma Ltd Azioni (URGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):